Frazier Lifesciences Acquisition Corp financial data

Industry
Blank Checks
Location
Two Union Square, 601 Union Street, Suite 3200, Seattle, WA
State of incorporation
Cayman Islands
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2022 - Nov 9, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 62.4 % -90.7%
Debt-to-equity -114 % +2.5%
Return On Equity 49.9 %
Return On Assets -2.61 % -211%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 4.96M USD +427%
Operating Income (Loss) -5.08M USD -389%
Net Income (Loss) Attributable to Parent -3.64M USD -211%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 788K USD -32.2%
Assets, Current 445K USD -54%
Assets 139M USD +0.22%
Accounts Payable, Current 945K USD +1997%
Accrued Liabilities, Current 2.86M USD +1343%
Liabilities, Current 3.81M USD +1449%
Liabilities 12.2M USD +47.7%
Retained Earnings (Accumulated Deficit) -11.7M USD -60.1%
Stockholders' Equity Attributable to Parent -11.7M USD -60.1%
Liabilities and Equity 139M USD +0.22%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -394K USD -94.4%
Net Cash Provided by (Used in) Financing Activities -45K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 376K USD -40.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 0 USD
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%